Combination of citicoline and piracetam is available in market as fixed dose combination in film coated tablet with dose of citicoline 500 mg and piracetam 800 mg. It has been approved by DCGI in the year 2010. This combination is chemically and pharmalogically safe.
The neuroprotective properties of the nootropic agent piracetam together with reported hemorrheologic and antithrombotic effects provided the rationale for the evaluation of piracetam in acute stroke. Pilot studies showed an increase in compromised regional cerebral blood flow and Improvement in motor function, aphasia and level of consciousness
A meta-analysis has been performed including nineteen double blind, placebo controlled studies with piracetam in patients suffering from dementia or cognitive impairment in the elderly.
Piracetam as an adjuvant to speech therapy improves recovery of various language functions, and this effect is accompanied by a significant increase of task-related flow activation in eloquent areas of the left hemisphere